| |AUGUST 20268TOP STORIESLUPIN'S NEW DEAL COULD BE A GAME CHANGER IN OPHTHALMOLOGYFIRST FDA-APPROVED GSDIA GENE THERAPY COULD CHANGE TREATMENT GLENMARK SCORES WITH USFDA APPROVAL FOR NASAL SPRAYWEGOVY PILL ENTERS NEW TRIAL TO FIND THE LOWEST EFFECTIVE DOSEPERSONALIZED MELANOMA VACCINE CLEARS MAJOR PHASE 3 TESTOphthalmology is becoming a stronger specialty-care focus for Lupin as the company expands its European eye-care business through VISUfarma. Lupin announced an exclusive licensing agreement with Visus Therapeutics for YUVEZZI, a once-daily ophthalmic treatment for adult presbyopia.The deal covers the European Union, UK, Switzerland, Norway and Iceland. It follows Lupin's acquisition of VISUfarma in April and adds a differentiated presbyopia product to its growing ophthalmology portfolio. The agreement could also strengthen Lupin's European specialty-care presence as the company expands beyond established eye care categories and targets new treatment opportunities. POUltragenyx Pharmaceutical's gene therapy Genglycos has received U.S. FDA approval for glycogen storage disease type Ia (GSDIa). The gene therapy is the first FDA-approved treatment for the rare metabolic disorder. GSDIa, also known as Von Gierke disease, affects about 1,500 to 2,500 people in the U.S.The inherited disorder is caused by a deficiency of an enzyme needed to release glucose from the liver. This The latest USFDA approval has given Glenmark Pharmaceuticals another entry into the US respiratory market with its Fluticasone Propionate Nasal spray. The company Wegovy pill has entered a new late-stage clinical trial as Novo Nordisk looks for the lowest dose that can still deliver meaningful weight loss. The study could help the company offer more flexible treatment options for people using oral semaglutide.Novo Nordisk started the Wegovy pill study, called OASIS 5, on August 12, 2026. The trial will run for 60 weeks and is expected to continue through 2028. It will include 450 adults with overweight or obesity. The company has not disclosed the exact lower doses that will be tested. The study will compare lower doses of oral semaglutide with a placebo. It will assess weight loss and other health benefits linked to the treatment. POMerck and Moderna's personalized melanoma vaccine has met key goals in a large Phase 3 trial. The mRNA-based treatment was tested with Merck's Keytruda in high-risk melanoma patients. The companies said the combination significantly improved recurrence-free survival. It also improved distant metastasis-free survival compared with Keytruda alone.The results mark the first successful Phase 3 test for an mRNA cancer vaccine of this kind. The Phase 3 trial enrolled 1,137 patients with surgically removed stage IIB to IV melanoma. These patients faced a high risk of their cancer returning or spreading. Patients received either Intismeran with Keytruda or Keytruda alone. Intismeran is the treatment's generic name and was earlier known as V940 or mRNA-4157. POcan lead to dangerous drops in blood sugar. Genglycos is designed to address the underlying cause of the disease. It helps the body break down glycogen and produce glucose. This could reduce patients' dependence on raw cornstarch to control blood sugar. POreceived the final approval on August 20, 2026, for a generic product equivalent to Haleon's Flonase nasal spray.The product will add to Glenmark's respiratory portfolio in the United States. This approval gives the company access to a market that recorded about USD 295.2 million in annual sales for the 12 months, according to IQVIA data. Glenmark Pharmaceuticals will distribute the product across the US market. PO
< Page 7 | Page 9 >